Over its 43 years of existence since becoming the first NCI cooperative group, the Children's Cancer Group (CCG) has enrolled greater than 48,000 patients on therapeutic studies, greater than 24,000 of whom were alive at last contact and expected to experience greater than 1,600,000 person-years of life saved. During 1993-1997, with patients residing in 48 states, CCG had a record high total of 15,963 entries onto therapeutic or biologic studies of patients. During 1997, record year-high totals were achieved for all (4,888), therapeutic (2,497) and biologic (1,603) study entries and the number of patients in active follow-up (18,000). The 5-year survival of children entered onto studies for treatment of newly-diagnosed cancer increased from 63 percent of 6,307 children enrolled in 1985-89 to 73 percent of 8,628 children enrolled in 1990-94. Pediatric cancer patients monitored by the national SEER program, most of whom are managed at CCG institutions, are projected to have their survival plateau increase from 76 percent to 82 percent for patients diagnosed in 1992 and 1997, respectively. With 182 trials in progress or development, 2881 clinical and laboratory investigators, and 120 member institutions, CCG will continue to help improve understanding, diagnosis, and treatment of pediatric cancers by conducting controlled clinical trials, performing translational research, investigating the biology and epidemiology of childhood cancers, discovering new therapeutic agents, developing new diagnostic and treatment modalities, enhancing life during and after cancer treatment, and disseminating the advances achieved to improve the outcome of all children with cancer. To achieve these goals, the CCG will conduct important Phase I, II and III trials that are designed to lead to more effective and less toxic therapies. A new biology and translational research program and a revised matrix organization will assure that CCG trials are hypothesis driven, scientifically meritorious, multidisciplinary, and inclusive of translational research. Special targets for 1998-2003 include central nervous system tumors, the adolescent gap in clinical trial participation, a premiere young investigator program, and establishment of a research development fund for CCG investigators. Strategies for acute leukemias, lymphoma, Hodgkin's disease, brain tumors, neuroblastoma, bone tumors, and soft-tissue tumors have been developed, including intergroup studies, that have a target to raise the overall survival plateau of all children with cancer in the U.S. by 5 percent, to 87 percent, by the year 2003.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA013539-27
Application #
2731830
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
1976-12-01
Project End
2002-11-30
Budget Start
1999-01-05
Budget End
1999-11-30
Support Year
27
Fiscal Year
1999
Total Cost
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
Bouffet, Eric; Allen, Jeffrey C; Boyett, James M et al. (2016) The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience. J Neurosurg Pediatr 17:453-9
Dupuis, L Lee; Lu, Xiaomin; Mitchell, Hannah-Rose et al. (2016) Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group. Cancer 122:1116-25
Mitchell, Hannah-Rose; Lu, Xiaomin; Myers, Regina M et al. (2016) Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331. Int J Cancer 138:332-9
Hastings, Caroline; Gaynon, Paul S; Nachman, James B et al. (2015) Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (?200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Br J Haematol 168:533-46
Salzer, Wanda L; Jones, Tamekia L; Devidas, Meenakshi et al. (2015) Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group. Pediatr Blood Cancer 62:414-8
Linabery, Amy M; Erhardt, Erik B; Richardson, Michaela R et al. (2015) Family history of cancer and risk of pediatric and adolescent Hodgkin lymphoma: A Children's Oncology Group study. Int J Cancer 137:2163-74
Winter, Stuart S; Dunsmore, Kimberly P; Devidas, Meenakshi et al. (2015) Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer 62:1176-83
Linabery, Amy M; Li, Wenchao; Roesler, Michelle A et al. (2015) Immune-related conditions and acute leukemia in children with Down syndrome: a Children's Oncology Group report. Cancer Epidemiol Biomarkers Prev 24:454-8
Myers, Regina M; Balsamo, Lyn; Lu, Xiaomin et al. (2014) A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Cancer 120:1417-25
Venkatramani, Rajkumar; Spector, Logan G; Georgieff, Michael et al. (2014) Congenital abnormalities and hepatoblastoma: a report from the Children's Oncology Group (COG) and the Utah Population Database (UPDB). Am J Med Genet A 164A:2250-5

Showing the most recent 10 out of 458 publications